Marihuana Regulation and Taxation Act (MRTA) The Marihuana Regulation & Taxation Act (MRTA) was signed into law on March 31, 2021 legalizing adult-use cannabis (also known as marijuana, or WASHIINGON — The Consumer Brands Association on July 22 renewed its call for urgent government action on cannabidiol (CBD) regulation in letters addressed to Dr. Janet Woodcock, acting commissioner of the Food and Drug Administration, and Senator Ron Wyden of Oregon, chairman of the Senate Committee on Finance. The letter to Dr. Woodcock from Betsy Booren, CBA’s senior vice president, regulatory affairs, stated the “FDA stance on CBD products is not working” and a regulatory framework for CBD products is “needed now to protect consumers, . . .
Marihuana Regulation and Taxation Act (MRTA)
The Marihuana Regulation & Taxation Act (MRTA) was signed into law on March 31, 2021 legalizing adult-use cannabis (also known as marijuana, or recreational marijuana) in New York State. The legislation created a new Office of Cannabis Management (OCM) governed by a Cannabis Control Board to comprehensively regulate adult-use, medical, and hemp cannabis. The OCM will issue licenses and develop regulations outlining how and when business can participate in the new industry.
Proposed Rule Making
The regulatory process in the State of New York is governed primarily by Article 2 of the State Administrative Procedure Act (SAPA) . This process is administered in the Office of Cannabis Management Legal Division .
To initiate a regulatory proposal, SAPA requires submission of a Notice of Proposed Rulemaking to the Secretary of State for publication in the New York State Register . If no public hearing is required, the notice must precede adoption by at least 60 days (45 days for revised rulemaking). Publication by the Secretary of State is the primary means of giving notice of proposed actions. However, any person or entity may file a standing request to receive notices from the Department directly.
If the text of the proposed notice exceeds 2,000 words, only a description of the subject purpose or substance of the rule will be published in the New York State Register . Similarly, if the text of the Regulatory Impact Statement, Regulatory Flexibility Analysis, Rural Area Flexibility Analysis and/or the Job Impact Statement exceeds 2,000 words a summary is required. To ensure the widest possible and most timely outreach, in conjunction with submission to the Secretary of State, the Office will post the complete version of all regulatory notices at this website.
Questions or comments on the proposed regulations should be directed to: [email protected]
or mailed to us at:
New York State Office of Cannabis Management PO Box 2071 Albany, NY 12220
CBA to FDA: Urgent action required on CBD regulation
WASHIINGON — The Consumer Brands Association on July 22 renewed its call for urgent government action on cannabidiol (CBD) regulation in letters addressed to Dr. Janet Woodcock, acting commissioner of the Food and Drug Administration, and Senator Ron Wyden of Oregon, chairman of the Senate Committee on Finance.
The letter to Dr. Woodcock from Betsy Booren, CBA’s senior vice president, regulatory affairs, stated the “FDA stance on CBD products is not working” and a regulatory framework for CBD products is “needed now to protect consumers, ensure product safety and transparency, establish guardrails for legal product innovation and distribution in interstate commerce, and provide the clarity needed for manufacturers of these products.”
Ms. Booren summarized the FDA stance as holding fast to a position that CBD-containing dietary supplements and foods may not be marketed under the exclusionary clauses of the Food, Drug, and Cosmetics Act and that the use of these products may present serious safety concerns.
Currently, the FDCA prohibits any new dietary ingredient, food or beverage from entering interstate commerce if it has been studied or approved as a drug, as is the case with CBD. The FDA has the authority to exempt items from this prohibition but has yet to do so in the case of CBD.
Yet CBD products are legally produced and used across the nation since Congress legalized hemp and hemp-derived products in the 2018 farm bill. These products currently are regulated by state and not federal authorities. As a result, products produced in one state may not be transported for sale in another, and regulations relating to production, marketing and labeling may differ greatly from state to state.
“Consumer Brands believes Americans deserve to know the products they purchase are safe and of consistent quality,” Ms. Booren wrote. “Without FDA leadership, state legislatures are putting their own polices in place. There are currently 135 proposals in 38 states which further confuse the disparate CBD regulations already on states’ books…Unfortunately, well-intentioned state CBD regulations have created a confusing, conflicting regulatory patchwork that fails to establish uniform requirements for the safe formulation, production, labeling and marketing of these products.”
Ms. Booren said federal action also was needed to reduce widespread consumer confusion, including the misperception that FDA already regulates CBD.
“Consumer Brands’ recent poll found that 74% of American consumers either incorrectly assume or have no idea if CBD is regulated,” Ms. Booren wrote. “The market is growing, and Americans are using products without FDA oversight and without a good understanding of CBD. When asked to rate their knowledge of CBD on a scale of 1 to 10, consumers rated themselves an average of 3.3. This knowledge gap, in concert with the lack of federal regulation, should create urgency for FDA to engage.”
Ms. Booren conveyed six CBD-related stakeholder requests to Dr. Woodcock.
First, the FDA should provide an update on the current state of scientific data needed to determine the safety of CBD products and provide a roadmap on how to identify and address data/information gaps.
Second, the FDA should establish a regulatory framework where consumer packaged goods manufacturers should notify the agency of CBD-containing products and provide safety data for the FDA to review.
Third, the FDA should provide an update on its progress toward establishing a regulatory framework for CBD products and opportunities for stakeholders to share their knowledge and perspectives.
Fourth, the FDA should provide technical assistance to members of Congress in their efforts to ensure a timely development of a regulatory framework.
Fifth, the FDA and other federal agencies should continue to take enforcement actions against bad actors to remove unsafe CBD-containing products and those making misleading claims.
And sixth, while the new regulatory framework is being developed, the FDA should work with stakeholders to develop a plan that may be implemented to make certain those products currently in the market are subject to the new regulatory framework.
The letter to Mr. Wyden from Jen Daulby, CBA’s senior vice president, government affairs, expressed those same concerns and imperatives while voicing support to the senator’s efforts to advance the Hemp Access and Consumer Safety Act, S 1698.
Mr. Wyden, on behalf of himself and Senators Rand Paul of Kentucky and Jeff Merkley of Oregon, introduced that legislation on May 19. The bill aimed to ensure hemp-derived products are regulated by the FDA like other legal products used in dietary supplements, foods and beverages. The measure sought a congressional solution to what increasingly was viewed as a regulatory Gordian knot.